The global health landscape is witnessing a significant shift, largely driven by increasing consumer awareness and concern about weight management, obesity, and related health conditions like diabetes. This shift is notably reflected in the growing interest in GLP-1 (Glucagon-Like Peptide-1), a class of drugs originally developed for diabetes treatment. GLP-1 receptor agonists, such as semaglutide, have garnered attention not only for their effectiveness in blood sugar regulation but also for their impact on weight loss.
